계명대학교 의학도서관 Repository

A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer

Metadata Downloads
Author(s)
Jae Jin LeeSi-Young KimHyun-Cheol ChungKyung-Hee LeeHong-Suk SongWon-Ki KangYoung-Seon HongIn-Sil ChoiYoung Yeul LeeIn-Sook WooJin-Hyuk Choi
Keimyung Author(s)
Song, Hong Suk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer Chemotherapy and Pharmacology
Issued Date
2009
Volume
63
Issue
6
Abstract
Purpose : This study was conducted to evaluate the safety and efficacy of S-1 and paclitaxel combination therapy for patients with advanced gastric cancer.
Methods : Eligible patients had previously untreated advanced or relapsed gastric cancer with measurable lesion(s) and an ECOG PS of 0-2. Treatment consisted of S-1 35 mg/m2 p.o. b.i.d. on days 1-14 followed by a 7-day off plus paclitaxel 70 mg/m2 i.v. on days 1 and 8 of a 21-day cycle. Fifty-six patients (M/F = 37/19) were enrolled. The median age was 59 years. The median number of cycles administered was six (range 1-18). Out of the 53 patients evaluated, there was 1 (1.9%) CR, 20 (37.7%) confirmed PRs, 5 (9.4%) unconfirmed PRs, 21 (39.6%) SDs, and 6 (11.3%) PDs. The objective tumor response was 39.6%. The median time to progression was 29 weeks. The median survival was 51 weeks. All 56 patients were assessed for treatment safety. The treatment was well tolerated with grade 3/4 neutropenia in 20%/13%, grade 3 febrile neutropenia in 7%, grade 2/3 diarrhea in 9%/4%, vomiting in 11%/0%, stomatitis in 4%/4%, and neuropathy in 4%/0% of patients.
Conclusion : S-1 and paclitaxel combination treatment is an effective regimen with a favorable toxicity profile in patients with advanced gastric cancer.
Keywords : Advanced gastric cancer, Chomotherapy, First Line, Paclitaxel, Phase II, S-1
Keimyung Author(s)(Kor)
송홍석
Publisher
School of Medicine
Citation
Jae Jin Lee et al. (2009). A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. Cancer Chemotherapy and Pharmacology, 63(6), 1083–1090. doi: 10.1007/s00280-008-0818-3
Type
Article
ISSN
0344-5704
Source
http://lps3.link.springer.com.proxy.dsmc.or.kr/article/10.1007%2Fs00280-008-0818-3
DOI
10.1007/s00280-008-0818-3
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35292
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.